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Abstract
Pterygium is a fleshy, inflamed, overgrowth of the conjunctiva that can invade the visual axis and cause vision
loss. Histologically, pterygia tissue shows overexpression of angiogenic factors. Potassium dobesilate (KD)
and resveratrol (RES) are known to inhibit angiogenesis and thereby may be useful agents in reducing
pterygia size and inflammation.
This study aimed at developing and characterizing three ophthalmic formulations each of KD, RES, or
KD:RES 10:1. The formulations for the individual and dual drug combination are prepared in normal saline
(NS) with a viscosity enhancer (10% polyethylene glycol 400; PEG 400) or as a sol-gel using 10% PEG 400
and 21% Pluronic® F127. All formulations contained either 25 mg of KD, 2.5 mg of RES, or a combination of
KD:RES 10:1 ratio and were stored at room temperature in the dark. The two types of formulations are tested
to provide flexible dosing schedules of once a day (Pluronic ® F127) or twice a day (NS+PEG 10%).
The physical and chemical stability of these formulations was assessed over a 28-day period, in triplicate, on
days 1, 7, 14, 21, and 28. Physical stability was determined by visual inspection and optical density
measurements at 295 nm (KD) and 306 nm (RES). Chemical stability was assessed by Reverse Phase High
Performance Liquid Chromatography (RP-HPLC) using a C18 column and a DAD detector at 295 nm (KD)
and 306 nm (RES). The effect of the compounds on the proliferation of human umbilical vein endothelial
cells (HUVEC) was used to assess the anti-angiogenic properties of KD and RES. Cell viability of HUVEC
was determined using Cell-Titer Blue® 24-hours post-treatment with KD, RES, or the combination.
Formulations 5 and 6 demonstrated physical stability for 28 days when stored at room temperature protected
from light. Formulation 1 in NS underwent a color change from slight yellow to darker yellow by day 7.
Optical density measurements were significantly lower at day 21 and 28 when compared to day 1. The PEG
400 and sol-gel formulations did not undergo a color or optical changes during storage. All formulations were
chemically stable for 28 days as assessed by RP-HPLC using United States Pharmacopeia (USP) guidelines
for ophthalmic formulations. The anti-proliferative effect of KD, RES, and KD:RES combination in HUVEC
indicated that RES is a more potent anti-angiogenic agent as compared to KD. Combination index analysis of
the KD:RES formulation indicates the combination is more potent inhibitor of angiogenesis as compared to
the individual compounds.
Our study indicates that KD in combination with RES may be a viable alternative treatment to reduce
pterygium size and inflammation. The sol-gel formulation may enhance patient compliance as compared to
the solution formulations with once a day, overnight, dosing. Future work for this project lies in assessing the
microbiological stability of these formulations in vitro and determining effectiveness in vivo.
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ABSTRACT 
 
Pterygium is a fleshy, inflamed, overgrowth of the conjunctiva that can invade the visual 
axis and cause vision loss. Histologically, pterygia tissue shows overexpression of angiogenic 
factors. Potassium dobesilate (KD) and resveratrol (RES) are known to inhibit angiogenesis and 
thereby may be useful agents in reducing pterygia size and inflammation. 
 This study aimed at developing and characterizing three ophthalmic formulations each 
of KD, RES, or KD:RES 10:1.  The formulations for the individual and dual drug combination are 
prepared in normal saline (NS) with a viscosity enhancer (10% polyethylene glycol 400; PEG 
400) or as a sol-gel using 10% PEG 400 and 21% Pluronic® F127.  All formulations contained 
either 25 mg of KD, 2.5 mg of RES, or a combination of KD:RES 10:1 ratio and were stored at 
room temperature in the dark. The two types of formulations are tested to provide flexible 
dosing schedules of once a day (Pluronic ® F127) or twice a day (NS+PEG 10%).  
The physical and chemical stability of these formulations was assessed over a 28-day 
period, in triplicate, on days 1, 7, 14, 21, and 28. Physical stability was determined by visual 
inspection and optical density measurements at 295 nm (KD) and 306 nm (RES). Chemical 
stability was assessed by Reverse Phase High Performance Liquid Chromatography (RP-HPLC) 
using a C18 column and a DAD detector at 295 nm (KD) and 306 nm (RES). The effect of the 
compounds on the proliferation of human umbilical vein endothelial cells (HUVEC) was used to 
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assess the anti-angiogenic properties of KD and RES.  Cell viability of HUVEC was determined 
using Cell-Titer Blue® 24-hours post-treatment with KD, RES, or the combination.  
 Formulations 5 and 6 demonstrated physical stability for 28 days when stored at room 
temperature protected from light. Formulation 1 in NS underwent a color change from slight 
yellow to darker yellow by day 7. Optical density measurements were significantly lower at day 
21 and 28 when compared to day 1. The PEG 400 and sol-gel formulations did not undergo a 
color or optical changes during storage. All formulations were chemically stable for 28 days as 
assessed by RP-HPLC using United States Pharmacopeia (USP) guidelines for ophthalmic 
formulations. The anti-proliferative effect of KD, RES, and KD:RES combination in HUVEC 
indicated that RES is a more potent anti-angiogenic agent as compared to KD.  Combination 
index analysis of the KD:RES formulation indicates the combination is more potent inhibitor of 
angiogenesis as compared to the individual compounds.  
Our study indicates that KD in combination with RES may be a viable alternative 
treatment to reduce pterygium size and inflammation. The sol-gel formulation may enhance 
patient compliance as compared to the solution formulations with once a day, overnight, 
dosing. Future work for this project lies in assessing the microbiological stability of these 
formulations in vitro and determining effectiveness in vivo. 
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INTRODUCTION 
 
Introduction 
Pterygium is a fleshy, inflamed, overgrowth of the conjunctiva that can invade the visual 
axis and cause vision loss. Pterygium is derived 
from the Greek word “pterygion”, which means a 
small wing (1).  Pterygium usually forms over the 
prelimbal conjunctiva and extends into the corneal 
surface (2). Clinically it presents as a non-malignant 
slow growing proliferation of wing shaped 
fibrovascular lesion (41).   
 
Clinical Features and Epidemiology 
Typical clinical presentation of a pterygium is separated into two groups, those with a 
minimal proliferating pterygium or those with a rapidly growing pterygium. The latter tends to 
be elevated with a fibrovascular component and the former has a less fibrovascular and flatter 
appearance (2). If excised, the first group tends to recur less frequently, while the second group 
takes a more aggressive clinical course with a greater likelihood of recurrence after excision (2).  
Pterygia are more common in individuals within the “pterygium zone,” defined as 40 
north and south of the equator (4). Within this zone, prevalence is up to 22% in the general 
population (5). Outside of this geographical location, pterygium prevalence is much less, around 
2% and typically found in those who work outdoors due to increased exposure to sunlight (6, 7). 
Differences in lifestyles between genders can be attributed to a higher prevalence in males 
Figure 1. Example of a pterygium showing the 
vascularized wing-shaped lesion originating from 
nasal conjunctiva (3). 
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compared to females (6, 7). Prevalence of pterygium in migrant workers is similar to the 
“pterygium zone” at 22% (42). 
Chronic ocular surface irritation from sun exposure, wind, and dust are environmental 
factors also contributing to pterygium development (4, 5). UVA and UVB radiation (290-400 nm) 
(8) are the wavelengths most harmful to the front surface of the eye. At the molecular level, UV 
radiation creates activated free radicals. Tear film proteins, including lactoferrin, deactivate free 
radicals (9). However, the increased number of free radicals increases oxidative stress in 
pterygium tissue, and in turn, increases a number of proteins, like survivin, in comparison to a 
normal ocular surface (10). A variety of cytokines, growth factors, and growth factor receptors 
are expressed with the changes mediated by trauma caused by UV radiation (11). These factors 
are essential for normal cornea healing and repair but have altered expression in pterygium 
tissue. These factors include, the interleukin-1 (IL-1) system acts with tumor necrosis factor  
(TNF ). Together these lead corneal keratocytes to take on a repair role (12, 13). Specifically, 
IL-6 promotes epithelial cell migration through the induction of integrin receptors (14, 15) and 
IL-8 displays mitogenic and angiogenetic activity (16, 17). Previous literature have involved 
different growth factors in pterygium tissue including epidermal growth factor (EGF), heparin-
binding EGF (HB-EGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(b-FGF), platelet-derived growth factor (PDGF), transforming growth factor-ß (TGF-ß) and 
insulin-like growth factor binding proteins (IGF-BP) (11). VEGF is of particular interest because it 
is produced by corneal fibroblasts in response to harmful inflammatory stimuli, including UV 
radiation (39). When comparing normal conjunctiva to pterygium tissue, VEGF concentrations 
are increased as quantified by immunochemistry (18). 
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Current Treatments and Therapies 
Clinical treatment of pterygia includes surgical excision typically with anti-metabolite 
treatment during excision, -irradiation, or treatment with growth factor inhibitors. Simple 
surgical excision of removing the pterygium tissue from the anterior corneal surface was early 
pterygium treatment (19, 20).”Bare sclera” technique involves removing the pterygium and 
peri-limbal conjunctiva while suturing the remaining conjunctival rim to the sclera. After 
removal, it is believed the newly uncovered area would re-epithelialize with epithelial cells at 
the conjunctival rim (19, 21).  This technique has been shown to have recurrence of pterygium 
up to 50% (19). 
Another surgical removal technique used is a conjunctival flap or conjunctival graft. Both 
of these techniques aim to place normal tissue where the pterygium was. In addition to normal 
tissue, this can provide stem cells on the sclerocorneal limbal area (22, 23). If the pterygium 
removal creates too large of a conjunctival defect, a preserved amniotic membrane can be used 
instead a conjunctival graft (24). This commercially available tissue provides a surface for re-
epithelialization (24). With this more advanced excision surgery, recurrence rates can be 
decreased to as low as 10% (19, 22). 
Since recurrence is always a concern with surgical excision of pterygium, 
antimetabolites, like mitomycin-C (MMC), are typically used (19, 22). MMC is a product of 
Streptomyces caesiptosus, an antibiotic, and is capable of alkylating DNA to block transcription 
and translation (25, 26). During surgery, MMC (0.2-0.4 mg/mL) is typically applied on the 
episclera for no more than 2 minutes, in intervals (25). With this surgery adjunctive, the 
recurrence rate of pterygium is less than 10% (19, 22, 27). MMC is also used postoperatively in 
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eye drops (19, 28). Another antimetabolite, 5-fluorouracil (5-FU) can be used intra-operatively 
or as a post-operative subconjunctival injection (19, 28). 
Antimetabolites are effective in decreasing pterygium recurrence rates (19, 22, 27), 
however, there are serious complications that may arise including scleral melt or delayed 
healing (19). These complications may damage vision or require further surgery.  
Drawbacks of surgical excision of pterygia include the high incidence of recurrence and 
the cost associated with the procedure. Cost of surgery is typically between $1800-2000 and 
insurance will cover much of the surgery (29), if the growth affects vision, but is not always 
affordable for patients without insurance, like migrant farm workers who typically fall below 
the poverty level (43). 
-irradiation is another option for pterygium removal. It has been one of the first 
attempts to remove pterygium (30, 31). The procedure involves delivering -irradiation by 
strontium-/yttrium-90 sources and this reduces cells responsible for pterygium recurrence (32). 
Endophthalmitis is a potential complication that can threaten vision (19).  
Growth factor inhibitors (anti-VEGF monoclonal antibodies) are used intraocularly for 
treatment of neovascular conditions like exudative macular degeneration and proliferative 
diabetic retinopathy (33). Bevacizumab (Avastin, Genentech) is a recombinant monoclonal 
antibody and Ranibizumab (Lucentis, Genetech) is a fragment, both of which are directed at 
VEGF (33). Bevacizumab has been studied in pterygium treatment (34, 35) but there are 
significant systemic side effects, including cardiovascular toxicity (33). Looking at VEGF 
expression in individual pterygium tissue can be used to determine if Bevacizumab or other 
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anti-VEGF treatment can be used to minimize recurrence of pterygium and systemic side 
effects.  
 
Objective of Study 
Since inflammation and angiogenesis are implicated in pterygia progression, a potential 
low cost, nonsurgical therapeutic option could include the use of agents targeted against 
inflammation and angiogenesis in a topical formulation. In a recent case study published in the 
British Medical Journal (36), a 53 year-old male patient exhibiting primary pterygium was 
treated with potassium dobesilate (KD), an anti-inflammatory with potential anti-angiogenic 
effects (37). The patient received KD formulated at 25 mg/mL in artificial tears administered as 
two drops twice daily for two weeks.  At the end of the treatment period, a clear regression in 
the pterygium was observed and the patient remained recurrence free at 2 months post-
treatment.  The authors speculated that the anti-angiogenic effects of the KD were responsible 
for the effectiveness of the treatment.  However, the anti-angiogenic effects were never 
directly assessed and the follow-up time of 2 months may not have been enough to fully 
evaluate this treatment regimen.  Additionally, other known anti-angiogenic agents like 
resveratrol (RES) (38) were not evaluated. Thus, objective of our work is to develop several 
stable ophthalmic formulations of KD and RES alone and in combination to assess the anti-
angiogenic effects of these agents alone and in combination for future development as low 
cost, alternative treatments for pterygium. 
The combination KD:RES formulation was pursued to determine if the use of two anti-
angiogenic agents may have a synergistic effect in inhibiting angiogenesis. The formulations 
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were characterized in terms of their physical and chemical stability. To assess the degree of 
anti-angiogenic effects of these compounds, cell proliferation studies were conducted in 
Human Umbilical Vein Endothelial Cells (HUVEC).  We hypothesize that one or more of the 
formulations containing KD, RES, or KD:RES will demonstrate physical and chemical stability and 
the compounds will demonstrate anti-angiogenic effects in vitro.  Upon completion of this work 
we anticipate having one or more formulations that can be tested further in vivo for efficacy in 
treating pterygia in a topical manner with a larger cohort. 
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MATERIALS AND METHODS 
Materials 
 KD was obtained from Pfaltz and Bauer (Waterbury, CT) and RES from TCI America 
(Portland, OR). Polyethylene glycol 400 (PEG 400), a 10% solution was obtained from VWR 
(Radnor, PA), sodium perborate from Spectrum Chemicals (New Brunswick, NJ) and normal 
saline from Fischer Scientific (Pittsburgh, PA). Pluronic® F127 was kindly donated by BASF 
(Florham Park, NJ). All other chemicals and solvents (HPLC grade) were purchased from VWR 
(Radnor, PA). Human Umbilical Vein Endothelial Cells (HUVEC) and Medium Kit consisting of 
basal medium and supplement pack were purchased from PromoCell (Heidelberg, Germany). 
Cell-Titer Blue® cell viability assay was purchased from Promega (Madison, WI). Other cell 
culture supplies, including trypsin with EDTA, were obtained from VWR (Radnor, PA). 
 
Formulation Preparation  
Ophthalmic formulations of varying 
viscosity were prepared with KD, RES, or KD:RES 
10:1 as the active drug (Table 1). All formulations 
contained either 25 mg of KD, 2.5 mg of RES, or a 
combination of KD:RES 10:1 ratio (25 mg KD: 2.5 
mg RES). The formulations for the individual and 
dual drug combination were prepared in normal 
saline (NS) with a viscosity enhancer (10% PEG 
400) or as a sol-gel using 10% PEG 400 and 21% 
 Drug Vehicle 
Formulation 1 KD NS 
Formulation 2 RES NS 
Formulation 3 KD + RES NS 
Formulation 4 KD 21% F127 
Formulation 5 RES 21% F127 
Formulation 6 KD + RES 21% F127 
Table 1 KD and RES formulations for stability 
testing. All formulations contained 0.005% sodium 
perborate and 10% PEG. 
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Pluronic® F127.  The sol-gel formulation was optimized to gel at 37° C, to mimic physiological 
temperature and ensure extended contact time on the ocular surface post-administration. All 
formulations were preserved using with 0.005% sodium perborate. Once prepared all 
formulations were stored at room temperature and protected for light.  All formulations were 
assessed for physical and chemical stability, as well as anti-angiogenic effects in cell culture.   
 
Formulation Evaluation-Physical Stability 
Physical stability of KD and RES formulations was completed over a 28-day period. 
Assessment of physical stability was performed by visual inspection and optical density 
measurements on days 1, 7, 14, 21, and 28.  Optical density measurements were performed at 
295 nm (KD) and 306 nm (RES) using a BioTek Synergy 2 spectrophotometer. Vehicles without 
any drug(s) were used as controls. Data for the visual inspections is presented in tabular format 
and optical density measurements are presented as Mean OD  SD of three replicates.  
 
Formulation Evaluation- Chemical Stability 
RP-HPLC was used to determine chemical stability over a 28-day period by UV detection 
at 295 nm (KD) and 305 nm (RES) with Agilent 1200 series instrument. The Agilent 1200 HPLC is 
equipped with a vacuum degasser, binary pump, autosampler, thermostatted column oven and 
a diode array detector (DAD).  A Zorbax SB-C18 column (Agilent Technologies) stabilized at 40° 
C with a mobile phase of H2O:ACN 70:30 stabilized with 1 % methanol and 0.1% H3PO4  at a flow 
rate of  0.3 mL/min.  Samples of 3 µL were injected and KD and RES were detected at 295 nm 
and 305 nm respectively. Retention time for KD was 0.57 min and RES was 1.20 min. Samples 
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were diluted 1:100 in methanol and assessed on days 1, 7, 14, 21, and 28. The calibration 
curves for both drugs with the line of best-fit equation and goodness of fit (r2) are provided in 
Figure i and Tables ii and iii, in Appendix A.  Stability data for three replicates is reported as 
Mean drug concentration  SD. 
 
Formulation Evaluation- In vitro Anti-angiogenic Effect Assessment 
 Anti-angiogenic properties of KD and RES were tested with HUVEC cell line between the 
passages of two and five. Cells were cultured in DMEM (Dulbecco’s Modified Eagle Medium) 
with supplemental growth mix (PromoCell) following the protocols provided by PromoCell. Cells 
were plated at a density of 10,000 cells/well in a 96-well plate and allowed to attach for 24 
hours. Cells were treated for 24 hours with KD, RES, and KD:RES 10:1 ratio at RES 0.01-1,000 
µM and KD from 1,000-10,000 µM and the same concentrations were used for the KD:RES 10:1.  
Post 24 hours, cells were assessed for viability using Cell-Titer Blue®. After a 2-hour incubation 
with the reagent, fluorescence was measured at 560EX/590EM on a BioTek Synergy 2 
spectrophotometer. Half minimal inhibitory concentration (IC50) values were calculated using 
GraphPad prism (La Jolla, CA) and viability data is presented as mean IC50  SD for KD, RES, and 
the combination KD:RES.  
Combination index (CI) analysis was calculated using CompuSyn software version 1.00 
from ComboSyn, Inc (Paramus, NJ) by Chou and Martin (44) with the KD:RES formulation to 
determine the interaction of each drug. The Median-Effect Principle and Combination Index-
Isobologram Theorem were used to determine whether KD and RES interaction was 
antagonistic or synergistic. The CI equation used was: 
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(D)1 
(Dx)1
+
(D)2
(Dx)2
= CI 
where D is Drug, and the subscripts 1 and 2 indicate each individual drug. Subscript x is the 
percent inhibition in cell proliferation with each particular drug. CI values less than 1 indicate 
synergistic drug effects, while CI values greater than 1 indicate antagonism, and a CI value equal 
to 1 shows additivity. The CI can be calculated for different fractions of cells affected (fa). 
Plotting CI vs fa shows the interaction at all affected levels (1-99%) for a given combination of 
drugs. Mean CI vs fa plot is shown for passage five of HUVEC cells in Figure 4B. 
 
Statistical Analysis 
Two-way ANOVA is utilized to determine statistical significance at a p-value of 0.05 for 
physical stability. Chemical stability was analyzed according to USP guidelines for ophthalmic 
preparations.  Statistical Analysis was performed using GraphPad Prism (La Jolla, CA). 
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RESULTS 
 
Formulation Preparation  
Formulations 2 and 3 were unable to be tested due to RES precipitating immediately 
when placed in NS. RES has low water solubility (0.003mg/mL) (47) and formulations 2 and 3 
use only normal saline as the vehicle, therefore, only formulations 1, 4, 5, and 6 were prepared 
and assessed for physical and chemical testing.  
 
Formulation Evaluation-Physical Stability 
 KD in NS (Formulation 1) had a slight yellow color on day 1. During visual inspection on 
day 7, the yellow color changed to a deeper yellow. The color remained unchanged for the rest 
of the 28-day period. KD in formulations 4 and 6 did not undergo any color change during the 
28-day period. Additionally, formulations containing RES, formulations 5 and 6, remained 
colorless for the 28-day period. Visual inspection data can be found in Table 2 below.   
 
 Optical density measures for each formulation can be found in Figure 2. Formulations 1, 
4, and 6 were assessed at 295nm to optimally detect KD. Formulations 1 and 4 demonstrated a 
 KD in NS KD in 21% F127 RES in 21% F127 KD:RES in 21% F127 
 Formulation 1 Formulation 4 Formulation 5 Formulation 6 
Day Color Clarity Color Clarity Color Clarity Color Clarity 
1 Slightly yellow Clear Colorless Clear Colorless Clear Colorless Clear 
7 Deeper yellow Clear Colorless Clear Colorless Clear Colorless Clear 
14 Deeper yellow Clear Colorless Clear Colorless Clear Colorless Clear 
21 Deeper yellow Clear Colorless Clear Colorless Clear Colorless Clear 
28 Deeper yellow Clear Colorless Clear Colorless Clear Colorless Clear 
Table 2: Color and clarity of KD and RES formulations (n = 4) by visual inspection for physical stability measurements 
over a 28-day period.   
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statistical decrease in optical density at day 21 and day 28 respectively, indicating a shorter 
shelf-life (Figure 2A).  Formulation 6 remained stable for the duration of the study with respect 
to both KD and RES (Figure 2A and 2B). RES in formulation 5 also showed no statistical changes 
in optical density measures for the 28-day period (Figure 2B). Two-Way ANOVA tables for 
formulations containing KD and RES are found in Appendix A (Table i). 
 
Formulation Evaluation- Chemical Stability 
 Chemical stability for each formulation was assessed by RP-HPLC over 28 days and is 
presented in Figure 3. Average concentration of each drug was determined from a collated 
calibration curve with KD and RES dissolved in various solvents and in the presence and absence 
of each other.  The individual conditions and the collated curves are presented in Appendix A.  
USP guidelines require ophthalmic formulations to remain within 10% of their labeled 
potency for the duration of their shelf-life. In formulations 1, 4, and 6, KD was measured at 
25mg and formulations 5 and 6 RES was measured at 2.5mg. Figure 3 shows concentration of 
Figure 2. Optical density measurements at 295 nm to detect the physical stability of KD over a 28-day period 
(n=4) (A). RES physical stability measured by optical density at 306 nm for the 28-day period (n=4) (B).  
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KD and/or RES in each formulation with USP drug concentration guidelines shown as dotted 
gray lines. KD concentration in formulation 1 is within the USP guidelines for the 28-day period. 
At day 28, the upper limit of USP guidelines is shown with formulation 1. Formulations 4 and 5 
show an increase in drug concentration from day 1 than what was weighed out for each 
sample. Pluronic® F127 cannot be shaken due to formation of air bubbles. Increased drug 
concentration of day 1 samples of formulations 4 and 5 may be due to incomplete mixing and is 
borne by the fact that for the remainder of the study the concentrations remained consistent. 
For the remaining 28-day period, formulations 4 and 5 fit within the USP guidelines for labeled 
drug concentration. KD concentration in formulation 6 is shown in purple and RES 
concentration in orange in Figure 3. KD and RES concentration falls below USP guidelines at day 
7. This point is an outlier due to the fact that post 7 days the concentrations remain within 10% 
of the labeled potency.  The variability at day 7 is also higher as compared to the rest of the 
days indicating that experimental error and not formulation failure is the reason for the drop in 
potency.  The remaining time course for KD and RES are within the usable range for ophthalmic 
preparations according to USP.  
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Figure 3. KD and RES concentrations in each formulation determined by RP-HPLC. USP guidelines for 
ophthalmic drug labeling shown by dotted gray lines. Data analyzed using GraphPad Prism.  
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Formulation Evaluation- In vitro Anti-angiogenic Effect Assessment 
  Anti-angiogenesis data for KD, RES, and the combination KD:RES are shown in Figure 4. 
IC50 values, minimum concentration of a compound to inhibit growth in 50% of cells, were 
calculated in GraphPad Prism (La Jolla, CA) and are shown in Figure 4A. Data was collected after 
a 24-hour treatment period with each drug. KD (n=4) showed the highest IC50 value of greater 
than 3500 µM. RES IC50 value was much lower than KD at 81 µM (n=4). The combination in a 
10:1 ratio gave an average IC50 value close to 53 µM (n=3) indicating less drug is needed to  
inhibit the growth of 50% of HUVEC cells. CI for all fa values are shown in Figure 4B for passage 
five of the HUVEC cells. KD and RES show a synergist effect (CI <1) up until 80% fa when the 
combination shows an antagonistic effect (CI>1). This indicates that at lower doses the 
combination is synergistic and can exhibit stronger anti-angiogenic effects.  Based on the IC50 
values in HUVECs future work will lie in exploring other combinations of KD:RES such as 40:1 to 
determine if this ratio is synergistic at all concentrations tested.  
Figure 4. Average IC50 values for KD (n=4), RES (n=4), KD:RES (n=3) calculated in GraphPad Prism (A). Combination 
index effects of KD:RES calculated in CompuSyn (B).  
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DISSCUSSION  
 Stable formulations in Pluronic® F127 vehicle gives a clinician a muco-adhesive option 
for pterygium treatment. Pluronic® F127 is a poloxamer made of triblock copolymers of 
polyethylene oxide-polypropylene oxide-polyethylene oxide that are thermoreversible and 
increases viscosity of a solution (49). In ophthalmic solutions, increased viscosity by use of 
carboxy methylcellulose is common, especially in artificial tears that are used to lubricate the 
ocular surface and increase the contact time of the artificial tear with the ocular surface (50). 
Increased contact with the ocular surface works to decrease the dosing schedule while 
maintaining a therapeutic concentration of a topical drug or artificial tear. For example, 
Vigamox® and Moxeza® are two pharmacologically identical antibiotics, but Vigamox® requires 
three times a day dosing, while Moxeza® is twice daily dosing (56, 57). 
 Stability of drugs can influence shelf-life and bioavailability of compounds. Our 
formulations showed no precipitates and formation of crystal precipitates over time is an 
indication of physical instability in a drug compound (51). RP-HPLC was used to detect KD and 
RES, as this method is highly sensitive. Each drug has different retention times and this allowed 
us to detect each compound when used in combination (formulation 6). Variation in chemical 
stability of each formulation, although usable based on USP guidelines, can be attributed to 
sample preparation. Each sample was individually weighed out using a calibrated Mettler 
Toledo AL54 decimal balance (Columbus, OH). Although the scale is calibrated, the 
measurement is not guaranteed. In the manufacturing setting, a stock solution for the batch 
would be prepared to eliminate the variability associate with individual measurements. 
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 The combination of KD and RES showed a synergistic effect in in vitro anti-angiogenic 
effect. Both KD and RES have been used to treat proliferative conditions like vitreal 
hemorrhages associated with diabetic retinopathy and melanoma (52, 53). Using the 
combination of KD and RES as anti-angiogenic compounds can help reduce the dosing schedule 
with the same effects to decrease pterygia vascularization. 
 
Clinical Relevance of Topical Pterygium Treatment 
 Looking at this study in a larger scheme, it is relevant for future pterygium treatment. As 
of right now pterygium treatment is limited. Surgical excision is indicated when a pterygium 
becomes so large it is having significant effects on the cornea, ocular irritation, or if a pterygium 
is cosmetically unappealing (3). Insurance companies typically consider pterygium removal an 
elective surgery until there are impacts on visual acuity (54) however; patients experience 
symptoms much sooner than this point. An ophthalmic solution with a sol-gel formulation can 
lead to earlier treatment for patients experiencing ocular irritation due to pterygia 
inflammation and growth and reduce the significant corneal effects. Additionally a topical 
treatment could potentially reduce the costs associated with this condition, since the mainstay 
surgical treatment costs $1800-2000 (29). Commonly patients with a pterygium are told to use 
artificial tears throughout the day to lubricate the ocular surface and to limit UV and wind 
exposure by wearing sunglasses (2). However, for many patients these are not enough to halt 
the progression of a pterygium because they do not stop the vascularization and the growth is 
continually fed a blood supply it needs to grow.  
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Many migrant and field workers surrounding the Pacific EyeClinics have higher UV 
exposure due to their occupation. Since UV exposure is such a large risk, a majority of patients 
seen in Pacific EyeClinics and on community vision screenings have pterygia. This study may 
lead to future in vivo trials with the population base surrounding the Pacific EyeClinics. 
 Our study has shown that two anti-angiogenic drugs are capable of stopping cell growth 
and are stable physically and chemically. This is the first step in being able to treat patients with 
our ophthalmic formulations before the visual consequences of pterygium growth and 
inflammation reach surgical levels.  
 
Limitations of study 
 Limitations of our study include the inability to test KD and RES anti-angiogenic 
properties on pterygia tissue. The formulations were tested in a cell line, which most closely 
resembled human vessels, a key component of vascularized pterygium tissue. Conclusions can 
be drawn to the efficacy of KD and RES on reducing pterygia vascularization from the results of 
the anti-angiogenesis study in HUVECs. The case study by Cuevas et. al. (36) showed the effect 
of KD in a one patient study and our study complements this by the anti-angiogenic effects we 
saw with KD and RES in the HUVEC cell line. We have established the stability of KD and RES, 
however, the role of RES on pterygia tissue has not been studied. Overall, our study has shown 
promising results for future treatment in vivo of vascularized pterygium. 
 
 
 
  
 
 
19 
Future studies 
 Given the stability profile of KD and RES, the next steps include further optimizing of the 
formulations and testing the microbiological stability of each formulation. USP Antimicrobial 
Effectiveness Testing (55) is the proposed methodology for microbiological testing. Candida 
albicans, Aspergillus niger, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus 
aureus are the microbes to be tested by USP guidelines with the formulations by inoculating 
each sample separately and determining the microbial killing rate. USP category 1 guidelines for 
ophthalmic products would be followed to determine the microbiological stability of each 
formulation and each formulation will be assessed in triplicate. 
Testing these formulations in vivo is another step to optimize KD and RES effects to 
decrease pterygia vascularization. The Pacific University EyeClinics has a large Hispanic patient 
population and the prevalence of pterygia is common in this population due to having 
occupations outdoors, including farming, construction, and grounds maintenance (40). As 
aforementioned, pterygia excision surgery is costly and not always an option for patients (29). 
The sol-gel formulation is ideal because it is meant for once a day dosing to reduce patient non-
compliance. Ideally, a future trial using our formulations to see their effects on reducing 
pterygia size and vascularization is the next step with the outcomes of our study. 
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CONCLUSION 
 Overall, this study has shown KD and RES are viable options for future treatment of 
pterygia. These drugs are stable physically and chemically over a 28-day period. KD and RES are 
able to inhibit angiogenesis in HUVEC cells, while the KD:RES 10:1 combination showed a 
synergistic effect and a lower required dosage to inhibit cell growth to the same level as KD or 
RES individually. Our study has shown promising results for future topical pterygium treatment. 
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APPENDIX A 
 
A 
ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 0.4218 8 0.05273 F (8, 40) = 15.17 P < 0.0001 
Row Factor 0.08792 2 0.04396 F (2, 40) = 12.65 P < 0.0001 
Column Factor 0.9812 4 0.2453 F (4, 40) = 70.58 P < 0.0001 
Residual 0.139 40 0.003476 
  
B 
ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 0.001306 4 0.0003264 F (4, 20) = 0.7658 P = 0.5599 
Row Factor 0.1199 1 0.1199 F (1, 20) = 281.4 P < 0.0001 
Column Factor 0.007777 4 0.001944 F (4, 20) = 4.561 P = 0.0088 
Residual 0.008525 20 0.0004262 
  
 
Table i. Two-Way ANOVA tables for optical density measures of physical stability for each formulation. 
Formulations containing KD are in A and formulations containing RES are in B. Columns in the table are SS is sums 
of squares, DF is degrees of freedom, MS is mean squares, and F is F statistic. Values obtained using GraphPad 
Prism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure i. Calibration curves for KD were prepared in methanol and 21% F127 with 10% PEG to mimic formulations 
(A). RES was prepared in 21% F127 with 10% PEG for each calibration curve (B). 
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Table ii. Individual calibration curves of KD and RES with various solvents and in the absence or presence of each 
other.  KD absorbance was quantified at 295 nm and RES at 306 nm following separation by RP-HPLC (n = 4). Linear 
regression curves and goodness of fit values were obtained using GraphPad Prism. 
 
 
 
 
 
 
 
Table iii. Collated KD and RES calibration curves utilized to analyze concentration of the compounds in various 
formulations. KD absorbance was quantified at 295 nm and RES at 306 nm following separation by RP-HPLC (n = 4). 
Linear regression curves and goodness of fit values were obtained using GraphPad Prism. 
 
 
 
 Linear Regression Equation Goodness of Fit (r2) 
KD Y = 9829x + 490.1 0.9979 
RES Y = 90258x – 189.9 0.9993 
HPLC Calibration Conditions Linear Regression Equation Goodness of Fit (r2) 
KD in Methanol Y = 7727x + 481.3 0.9999 
KD in F127 Y = 7517x + 498.4 1.0000 
KD in F127 + RES Y =8189x + 490.5 1.0000 
RES in F127 Y = 89274x – 261.6 0.9997 
RES in F127 + KD Y = 91241x – 118.2 0.9999 
